Ontology highlight
ABSTRACT:
SUBMITTER: Huber ML
PROVIDER: S-EPMC3283534 | biostudies-other | 2012 Feb
REPOSITORIES: biostudies-other
Huber Marie L ML Haynes Laura L Parker Chris C Iversen Peter P
Journal of the National Cancer Institute 20120109 4
Sipuleucel-T was approved by the US Food and Drug Administration on April 29, 2010, as an immunotherapy for late-stage prostate cancer. To manufacture sipuleucel-T, mononuclear cells harvested from the patient are incubated with a recombinant prostatic acid phosphatase (PAP) antigen and reinfused. The manufacturer proposes that antigen-presenting cells exogenously activated by PAP induce endogenous T-cells to attack PAP-bearing prostate cancer cells. However, the lack of demonstrable tumor respo ...[more]